Ribociclib Succinate Patent Expiration
Ribociclib Succinate is Used for treating HR-positive, HER2-negative advanced or metastatic breast cancer in combination with other endocrine-based therapies. It was first introduced by Novartis Pharmaceuticals Corp
Ribociclib Succinate Patents
Given below is the list of patents protecting Ribociclib Succinate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Kisqali | US10799506 | Ribociclib tablet | Apr 14, 2036 | Novartis |
| Kisqali | US12064434 | Ribociclib tablet | Apr 14, 2036 | Novartis |
| Kisqali | US9193732 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | Nov 09, 2031 | Novartis |
| Kisqali | US9868739 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | Nov 09, 2031 | Novartis |
| Kisqali | US8415355 | Pyrrolopyrimidine compounds and their uses | Mar 13, 2031 | Novartis |
| Kisqali | US8685980 | Pyrrolopyrimidine compounds and their uses | May 25, 2030 | Novartis |
| Kisqali | US8962630 | Pyrrolopyrimidine compounds and their uses | Dec 09, 2029 | Novartis |
| Kisqali | US9416136 | Pyrrolopyrimidine compounds and their uses | Aug 20, 2029 | Novartis |
| Kisqali | US8324225 | Pyrrolopyrimidine compounds and their uses | Jun 17, 2028 | Novartis |
Ribociclib Succinate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List